SC
Stempoint Capital Portfolio holdings
AUM
$311M
1-Year Return
15.22%
This Quarter Return
+5.14%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$399M
AUM Growth
+$65.3M
(+20%)
Cap. Flow
+$70M
Cap. Flow
% of AUM
17.55%
Top 10 Holdings %
Top 10 Hldgs %
51.04%
Holding
75
New
22
Increased
19
Reduced
6
Closed
24
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$15.1M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$14.7M |
| 3 |
Nuvalent
NUVL
|
$11.4M |
| 4 |
Immunovant
IMVT
|
$11.1M |
| 5 |
Alkermes
ALKS
|
$10.6M |
Top Sells
| 1 |
Arcutis Biotherapeutics
ARQT
|
$17.8M |
| 2 |
Amicus Therapeutics
FOLD
|
$15.8M |
| 3 |
Applied Therapeutics
APLT
|
$13.2M |
| 4 |
AUTL
Autolus Therapeutics
AUTL
|
$9.5M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$7.06M |
Sector Composition
| 1 | Healthcare | 99.62% |
| 2 | Financials | 0.38% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Protagonist Therapeutics
PTGX
$3.71B
| $5.47M | 1.37% |
+141,714
| New | +$5.47M |
|
|
SLRN
27
DELISTED
ACELYRIN
SLRN
| $5.35M | 1.34% |
1,704,825
+386,971
| +29% | +$1.22M |
|
28
Surrozen
SRZN
$107M
| $5.03M | 1.26% |
350,573
+167,655
| +92% | +$2.41M |
|
29
Mineralys Therapeutics
MLYS
$2.2B
| $4.93M | 1.23% |
+400,101
| New | +$4.93M |
|
30
Neumora Therapeutics
NMRA
$264M
| $4.54M | 1.13% |
+428,137
| New | +$4.54M |
|
31
EyePoint Pharmaceuticals
EYPT
$819M
| $4.32M | 1.08% |
+579,500
| New | +$4.32M |
|
32
Ultragenyx Pharmaceutical
RARE
$3.01B
| $4.28M | 1.07% |
+101,809
| New | +$4.28M |
|
33
89bio
ETNB
$1.28B
| $4.27M | 1.07% |
+545,800
| New | +$4.27M |
|
34
Cytokinetics
CYTK
$5.95B
| $3.93M | 0.98% |
83,576
+69,112
| +478% | +$3.25M |
|
|
CTNM
35
Contineum Therapeutics
CTNM
$308M
| $3.89M | 0.97% |
+265,833
| New | +$3.89M |
|
36
Edgewise Therapeutics
EWTX
$1.54B
| $3.54M | 0.88% |
132,706
+112,806
| +567% | +$3.01M |
|
37
Rocket Pharmaceuticals
RCKT
$349M
| $3.41M | 0.85% |
+270,983
| New | +$3.41M |
|
38
Jasper Therapeutics
JSPR
$43.7M
| $2.89M | 0.72% |
+135,244
| New | +$2.89M |
|
39
Tourmaline Bio
TRML
$645M
| $2.56M | 0.64% |
126,400
+70,877
| +128% | +$1.44M |
|
40
Enliven Therapeutics
ELVN
$1.19B
| $2.18M | 0.54% |
+96,716
| New | +$2.18M |
|
|
BBOT
41
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$798M
| $2.11M | 0.53% |
200,900
+900
| +0.5% | +$9.45K |
|
42
Protara Therapeutics
TARA
$122M
| $1.76M | 0.44% |
332,394
-610,463
| -65% | -$3.22M |
|
43
uniQure
QURE
$973M
| $1.59M | 0.4% |
+90,000
| New | +$1.59M |
|
|
PCSC
44
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $1.53M | 0.38% |
150,000
| – | – |
|
|
VRNA
45
Verona Pharma
VRNA
$9.19B
| $1.31M | 0.33% |
+28,136
| New | +$1.31M |
|
46
Cidara Therapeutics
CDTX
$1.65B
| $1.28M | 0.32% |
+47,642
| New | +$1.28M |
|
|
ATYR
47
aTyr Pharma
ATYR
$536M
| $726K | 0.18% |
+200,475
| New | +$726K |
|
|
TECX
48
Tectonic Therapeutic, Inc. Common Stock
TECX
$323M
| $436K | 0.11% |
+9,434
| New | +$436K |
|
49
Arcellx
ACLX
$4B
| – | – |
-60,076
| Closed | -$5.02M |
|
|
50
Applied Therapeutics
APLT
$67M
| – | – |
-1,554,586
| Closed | -$13.2M |
|